Lu S, et al. - Fruquintinib is a kinase inhibitor that selectively targets vascular endothelial growth factor receptors and, hence, tumor angiogenesis and lymphogenesis. Its efficacy as well as safety was assessed in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) who experienced disease progression after second-line chemotherapy. In this randomized, double-blind, placebo-controlled, multicenter phase II trial, with an acceptable safety profile, superiority of third- and fourth-line fruquintinib for advanced NSCLC was shown, relative to placebo.